Impact of Glycosylation on SARS-CoV-2 Infection and Broadly Protective Vaccine Design
Liao, H.-Y.; Huang, H.-Y.; Chen, X.; Cheng, C.-W.; Wang, S.-W.; Shahed-Al-Mahmud, M.; Chen, T.-H.; Lo, J. M.; Liu, Y.-M.; Ma, H.-H.; Chang, Y.-H.; Tsai, C.-Y.; Huang, P.-Y.; Chang, S.-Y.; Chao, T.-L.; Kao, H.-C.; Tsai, Y.-M.; Chen, Y.-H.; Chen, C.-Y.; Lee, K.-C.; Wu, C.-Y.; Jan, J.-T.; Lin, K.-I.; Cheng, T.-J. R.; Ma, C.; Wong, C.-H.
Show abstract
A major challenge to end the pandemic caused by SARS-CoV-2 is to develop a broadly protective vaccine. As the key immunogen, the spike protein is frequently mutated with conserved epitopes shielded by glycans. Here, we reveal that spike glycosylation has site-differential effects on viral infectivity and lung epithelial cells generate spike with more infective glycoforms. Compared to the fully glycosylated spike, immunization of spike protein with N-glycans trimmed to the monoglycosylated state (Smg) elicits stronger immune responses and better protection for hACE2 transgenic mice against variants of concern. In addition, a broadly neutralizing monoclonal antibody was identified from the Smg immunized mice, demonstrating that removal of glycan shields to better expose the conserved sequences is an effective and simple approach to broad-spectrum vaccine development. One-Sentence SummaryRemoving glycan shields to expose conserved epitopes is an effective approach to develop a broad-spectrum SARS-CoV-2 vaccine.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 96%
- Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants 95%
- Polyvalent mRNA vaccination elicited potent immune response to monkeypox surface antigens 94%
Similar papers in this journal
- A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines 96%
- Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes 95%
- Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants 95%
Similar papers in this journal
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 96%
- Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy 96%
- Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.